Search Results - "Celebi, John"

349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) by Algazi, Alain, Smith, William, Panella, Timothy, Shin, Dong, Fjaellskog, Marie-Louise, Celebi, John, Drumheller, Alice, Campbell, Jean, Pierce, Robert, Guarino, Michael

“…BackgroundEfficacy of anti-PD-1 therapy is attributed to the presence of infiltrating antigen-specific CD8+ T-cells. Despite the success of anti-PD-1 therapy,…”
Get full text

Safety/efficacy of a phase I/II study of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) by Smith, William, Celebi, John, Pierce, Robert, Drumheller, Alice, Csiki, Ildiko, Algazi, Alain Patrick

“…Abstract only e18510 Background: SNS-301 is a first-in-class immune activating agent targeting human aspartyl (asparaginyl) β-hydroxylase (ASPH). ASPH is…”
Get full text

Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) by Algazi, Alain Patrick, Shah, Dhaval, Smith, William, Panella, Timothy J., Shin, Dong Moon, Bruce, Justine Yang, Melhem, Ramzi, Campbell, Jean S., Abell, Lauren, Fjaellskog, Marie-Louise, Celebi, John K., Pierce, Robert Hamilton, Gramza, Ann Wild

“…Abstract only 6029 Background: The absence of infiltrating antigen-specific CD8+ T-cells at baseline is associated with low response rates to PD-1 blockade…”
Get full text